Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development, and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Orencia (abatacept), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Breyanzi (lisocabtagene maraleucel), Opdualag (nivolumab and relatlimab-rmbw), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), Sotyktu (deucravacitinib), Krazati (adagrasib), and Cobenfy (xanomeline and trospium chloride). Its other growth products include Augtyro, Onureg, Inrebic, Nulojix, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension).
Back to dashboard
Company Information
About this company
Key people
Christopher S. Boerner
Chairman of the Board, Chief Executive Officer
Cristian Massacesi
Executive Vice President, Chief Medical Officer, Head of Development, Member of the Leadership Team
Theodore R. Samuels
Lead Independent Director
Peter J. Arduini
Independent Director
Deepak L. Bhatt
Independent Director
Julia A. Haller
Independent Director
Michael R. McMullen
Independent Director
David V. Elkins
Executive Vice President, Chief Financial Officer, Member of the Leadership Team
Benjamin Hickey
President - RayzeBio Organization, Member of the Leadership Team
Lynelle Hoch
President - Cell Therapy Organization, Member of the Leadership Team
Amanda Poole
Executive Vice President, Chief People Officer, Member of the Leadership Team
Greg Scott Meyers
Executive Vice President, Chief Digital and Technology Officer, Member of the Leadership Team
Cari Gallman
Executive Vice President, General Counsel and Chief Policy Officer
Wendy Short Bartie
Executive Vice President, Corporate Affairs, Member of the Leadership Team
Adam Lenkowsky
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
Click to see more
Key facts
- Shares in issue2.92bn
- EPICBMY
- ISINUS1101221083
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$122.05bn
- Employees32,500
- ExchangeNew York Stock Exchange
- IndexS&P 500, TR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.